InterAct Therapeutics (IAT) is a preclinical company advancing its proprietary InterAct Print™ platform to deliver transformative gene therapies for metastatic cancers. Our lead candidate, IAT-S2, targets breast cancer-derived liver metastases (BCLM), a devastating orphan disease with no approved therapy and a 5-year survival rate below 10%. IAT-S2 introduces a transgene to hepatocytes, reprogramming the liver microenvironment to inhibit metastatic tumor growth. We are about 18 months from IND submission. We recently submitted to the FDA our INTERACT Meeting package and Orphan Drug Designation application. InterAct Print™ is a proprietary computational biology engine that identifies the genes most essential for metastatic colonization across different organs. Once validated in BCLM, it provides a repeatable framework to rapidly expand into other metastasis-dominant and oligometastatic indications. We have additional drug candidates in our pipeline.